Smith & Nephew buys into India, announces $300M share buyback as Q1 profits slide on flat sales

Smith & Nephew buys into India, announces $300M share buyback as Q1 profits slide on flat salesbuyback, India acquisition

Smith & Nephew (FTSE:SN, NYSE:SNN) said it bought into the mid-tier trauma business in India and announced a $300 million share buyback alongside lower 1st-quarter profits and flat sales.

The British medical device company said profits for the 3 months ended March 30 were $143 million, or 79¢ per share, on sales of $1.08 billion, for a bottom-line slide of 10.1% and a sales decline of 0.4% compared with Q1 2012.

Adjusted to exclude reorganization and acquisition costs, trading profits were $241 million, or 92.5¢ per share, down 4.4%.

"Smith & Nephew has consistently delivered revenue and earnings growth together with strong cash generation in the challenging markets of the last few years. In light of this, and our confidence in the continued execution of our strategic priorities, we have undertaken a major review of our capital allocation framework," CEO Olivier Bohuon said in prepared remarks."We will continue to invest in our growth products, franchises and geographies and maintain adequate headroom for further significant acquisitions. We have increased the level of dividend and moved to a progressive policy. Further to these commitments, today we are announcing the start of a share buy-back programme to return $300 million of surplus capital to our shareholders."

The company said it agreed to acquire Adler Mediequip, "a leading manufacturer and distributor of mid-tier, orthopaedic trauma products for the Indian market," and its Sushrut Surgicals brand, according to a press release. Along with the buyout of longtime Brazilian distribution partner Pró Cirurgia Especializada earlier this month, the acquisition spend is about $70 million, Smith & Nephew said.

The outlook for the rest of the year is unchanged, new CFO Julie Brown told analysts during a conference call.

"We do expect, however, to see some variation in performance at the product franchise level. In particular, Healthpoint is performing most strongly than we previously guided, and conversely, we’re seeing slightly lower hip and knee growth relative to the market than we had expected. In terms of margin, as you know, we expect to be below the 2012 level," Brown said. "We expect the revenue trends of Q1 to continue into Q2. We expect the 2nd half of the year to be stronger, as we benefit from new product introductions. The 2 sales days we lost in Q1 we will make up for in Q2 and in Q4 this year. And we expect Healthpoint growth to be over 20% for the full year. In terms of margin, the cost of this accelerated investment will start to come through in Q2, ahead of the benefits."

SNN shares were trading at $58.23 each as of about 1 p.m. today, up 2.0%.

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply